Production problems at an Emergent BioSolutions manufacturing plant put tens of millions of AstraZeneca doses under scrutiny, forcing the Biden administration to revise its plan for needy countries.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.